HC Wainwright & Co. Reiterates Buy on Denali Therapeutics, Maintains $90 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has reiterated its Buy rating for Denali Therapeutics, maintaining a price target of $90.
September 04, 2024 | 11:37 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated its Buy rating for Denali Therapeutics, maintaining a price target of $90, indicating confidence in the company's future performance.
The reiteration of a Buy rating and maintenance of a $90 price target by HC Wainwright & Co. suggests positive sentiment and confidence in Denali Therapeutics' future performance. This could lead to increased investor interest and a potential short-term price increase.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100